{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:19:23Z","timestamp":1787786363286,"version":"build-2784847793"},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The availability of new oral anticoagulants (NOACs) targeting either thrombin (dabigatran etexilate) or factor Xa (rivaroxaban and apixaban) for the prevention and treatment of thrombosis has been highly anticipated. NOACs have major pharmacologic advantages over vitamin K antagonists (eg, warfarin), including rapid onset\/offset of action, few drug interactions, and predictable pharmacokinetics, eliminating the requirement for regular coagulation monitoring. Regulatory agencies have approved several NOACs for specific indications based on the results of clinical trials demonstrating efficacy and safety that are at least as good, if not better, than warfarin (for stroke prevention in atrial fibrillation and treatment and secondary prevention of venous thromboembolism) or low-molecular-weight heparin, which is injectable (for initial treatment of venous thromboembolism and thromboprophylaxis in patients undergoing hip or knee arthroplasty). However, the adoption of this new therapeutic class into clinical practice has been slower than expected due to several factors including concerns regarding medication adherence without laboratory monitoring, uncertainty about dosing in some patient populations (eg, renal dysfunction, marked extremes of body weight), and higher drug costs compared with warfarin. Other issues are the current absence of specific antidotes for NOACs and assays to measure drug levels at most centers. The indications for NOACs on the market will expand and at least one additional agent (edoxaban) will likely gain approval within the next 2 years. As practitioners gain familiarity with the drugs and healthcare systems adapt to their use, NOAC use will increase substantially over time. Warfarin, however, will continue to be an appropriate anticoagulant choice for many patients.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.464","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T10:51:13Z","timestamp":1386327073000},"page":"464-470","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":177,"title":["Pros and cons of new oral anticoagulants"],"prefix":"10.1182","volume":"2013","author":[{"given":"Kenneth A.","family":"Bauer","sequence":"first","affiliation":[{"name":"Beth Israel Deaconess Medical Center and VA Boston Healthcare System, Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2019111703560256700_B1","first-page":"353","article-title":"The anticoagulants market","volume":"8","author":"Melnikova","year":"2009","journal-title":"Nat Rev"},{"key":"2019111703560256700_B2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1538-7836.2011.04321.x","article-title":"Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa","volume":"9","author":"Bauer","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111703560256700_B3","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2011-10-378950","article-title":"How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch","volume":"119","author":"Schulman","year":"2012","journal-title":"Blood"},{"key":"2019111703560256700_B4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/asheducation-2010.1.221","article-title":"Warfarin versus new agents: interpreting the data","volume":"2010","author":"Ansell","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019111703560256700_B5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/asheducation.V2012.1.536.3798545","article-title":"New oral anticoagulants: which one should my patient use?","volume":"2012","author":"Weitz","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2019111703560256700_B6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIRCULATIONAHA.111.031146","article-title":"Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism","volume":"125","author":"Granger","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"2019111703560256700_B7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCULATIONAHA.111.031153","article-title":"New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation","volume":"125","author":"Ansell","year":"2012","journal-title":"Circulation"},{"issue":"10","key":"2019111703560256700_B8","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1161\/ATVBAHA.110.203604","article-title":"Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin","volume":"30","author":"Eisert","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2019111703560256700_B9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2019111703560256700_B10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"2019111703560256700_B11","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111703560256700_B12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111703560256700_B13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111703560256700_B14","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"2019111703560256700_B15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jacc.2012.09.057","article-title":"Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)","volume":"61","author":"Patel","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2019111703560256700_B16","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Int Med"},{"issue":"20","key":"2019111703560256700_B17","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation"},{"issue":"3","key":"2019111703560256700_B18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med"},{"issue":"9","key":"2019111703560256700_B19","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111703560256700_B20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/CIRCOUTCOMES.112.967299","article-title":"National trends in oral anticoagulant use in the United States, 2007 to 2011","volume":"5","author":"Kirley","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"2019111703560256700_B21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/jth.12086","article-title":"Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?","volume":"11","author":"Rodriguez","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"26","key":"2019111703560256700_B22","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"issue":"9632","key":"2019111703560256700_B23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"issue":"26","key":"2019111703560256700_B24","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"issue":"9676","key":"2019111703560256700_B25","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"2019111703560256700_B26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies","volume":"105","author":"Turpie","year":"2011","journal-title":"Thromb Haemost"},{"issue":"1","key":"2019111703560256700_B27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1302\/0301-620X.93B1.24987","article-title":"Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study","volume":"93","author":"Jensen","year":"2011","journal-title":"J Bone Joint Surg Br"},{"issue":"26","key":"2019111703560256700_B28","first-page":"2499","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Einstein Investigators","year":"2012","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111703560256700_B29","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Einstein-PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111703560256700_B30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111703560256700_B31","first-page":"20","article-title":"Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies [abstract]","volume":"120","author":"B\u00fcller","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"2019111703560256700_B32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111703560256700_B33","article-title":"Treatment of cancer-associated thrombosis","author":"Lee","journal-title":"Blood"},{"issue":"17","key":"2019111703560256700_B34","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111703560256700_B35","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111703560256700_B36","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate-a novel reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111703560256700_B37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"2019111703560256700_B38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1586\/ehm.13.11","article-title":"Monitoring plasma levels of factor Xa inhibitors: how, why and when?","volume":"6","author":"Samama","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"2019111703560256700_B39","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1002\/ajh.23165","article-title":"Reversal of antithrombotic agents","volume":"87","author":"Bauer","year":"2012","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111703560256700_B40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11239-013-0923-y","article-title":"Reversal of target-specific oral anticoagulants","volume":"36","author":"Kaatz","year":"2013","journal-title":"J Thromb Thrombolysis"},{"issue":"19","key":"2019111703560256700_B41","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","article-title":"Anticoagulant options\u2013why the FDA approved a higher but not a lower dose of dabigatran","volume":"364","author":"Beasley","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111703560256700_B42","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc1112874","article-title":"Bleeding risk with dabigatran in the frail elderly","volume":"366","author":"Harper","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111703560256700_B43","doi-asserted-by":"crossref","first-page":"e002758","DOI":"10.1136\/bmjopen-2013-002758","article-title":"Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study","volume":"3","author":"S\u00f8rensen","year":"2013","journal-title":"BMJ Open"},{"issue":"9","key":"2019111703560256700_B44","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMe1307413","article-title":"Treating acute venous thromboembolism\u2013shift with care","volume":"369","author":"Cushman","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111703560256700_B45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/jhm.948","article-title":"Cost-related medication underuse: prevalence among hospitalized managed care patients","volume":"7","author":"Choudhry","year":"2012","journal-title":"J Hosp Med"},{"key":"2019111703560256700_B46","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","author":"Eikelboom","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/464\/1250559\/bep00113000464.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/464\/1250559\/bep00113000464.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:56:28Z","timestamp":1573962988000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/464\/20841\/Pros-and-cons-of-new-oral-anticoagulants"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.464","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}